SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Citigroup Initiates Coverage On Pliant Therapeutics with Buy Rating, Announces Price Target of $40

Citigroup analyst Joel Beatty initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Buy rating and announces Price Target of $40.

Benzinga · -
Citigroup analyst Joel Beatty initiates coverage on Pliant Therapeutics (NASDAQ: PLRX) with a Buy rating and announces Price Target of $40.